Njira L Lugogo MD
Asthma & COPD
Professor of Medicine, University of Michigan
Join to View Full Profile
380 Parkland PlazaAnn Arbor, MI 48103
Phone+1 734-998-7380
Dr. Lugogo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Clinical Expertise
- Refractory asthma
Education & Training
Duke University HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 2004 - 2007
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2001 - 2004
Virginia Commonwealth University School of MedicineClass of 2001
Certifications & Licensure
MI State Medical License 2017 - 2027
NC State Medical License 2001 - 2018
American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Fellows Teaching Award Pulmonary Division, University of Michigan, 2019
Clinical Trials
- Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma Start of enrollment: 2013 Mar 01
- PackHealth: Asthma Engagement Tool Start of enrollment: 2015 Aug 01
- Expansion of the COPD At-risk Module in 4 States BRFSS Telephone Health Surveys Start of enrollment: 2015 Jan 01
Publications & Presentations
PubMed
- 1 citationsResponse to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach.Eileen Wang, William Henley, Désirée Larenas-Linnemann, Lakmini Bulathsinhala, Trung N Tran
The Journal of Allergy and Clinical Immunology. in Practice. 2025-09-02 - 1 citationsEvaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts.Ramesh J Kurukulaaratchy, Anna Freeman, Aruna T Bansal, Latha Kadalayil, Eve Denton
The Lancet. Respiratory Medicine. 2025-09-01 - Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study.Njira L Lugogo, Praveen Akuthota, Kaharu Sumino, Sameer K Mathur, Autumn F Burnette
Advances in Therapy. 2025-09-01
Press Mentions
Dupilumab Reduces Airway Inflammation, Mucus Plugging in Moderate to Severe AsthmaFebruary 27th, 2024- NAVIGATOR Steers Uncontrolled Asthma Toward Calmer SeasMay 18th, 2022
- NAVIGATOR: Nearly Half of Patients with Severe, Uncontrolled Asthma Improved with TezepelumabMay 17th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
